InvestorsHub Logo
Followers 0
Posts 82
Boards Moderated 0
Alias Born 03/03/2015

Re: None

Friday, 08/18/2017 10:13:02 PM

Friday, August 18, 2017 10:13:02 PM

Post# of 6372
SJ, that is the bear case. It is a case that has some merit.

The bull case is that the past results in human trials are strong enough to give us confidence that when they get the 19 patients dosed, regardless of missed deadlines, the results will be good. Those results will provide the company with something of value. Enough value that they can strike a deal for much needed cash in exchange for a piece of future prexigerbersen sales and hopefully help getting it to market. They are so weak right now that they will not be able to get a good or even fair deal, but news of that deal will skyrocket the stock.

Eventually, long-term, it is quite possible they get a drug to market or multiple drugs to market with revenue potential of $10 billion per year, give or take. That will very likely require partnership with another, stronger, company. News of such a partnership could come within the next 12 months, more likely 24 months. I believe that would take the stock to $5.00+.

That is the bull case. It is a case that has some merit.

Still holding.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BPTH News